Also known as: Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company developing therapies for immune-mediated diseases. Its pipeline includes RASP modulators and ophthalmology-focused candidates such as reproxalap and ADX-2191.
The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
